301 related articles for article (PubMed ID: 37227492)
41. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
42. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
43. Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias.
Han X; Bueso-Ramos CE
Am J Clin Pathol; 2007 Apr; 127(4):528-44. PubMed ID: 17369128
[TBL] [Abstract][Full Text] [Related]
44. Clinical use of CAR T-cells in treating acute lymphoblastic leukemia.
Korkmaz S
Transfus Apher Sci; 2023 Apr; 62(2):103666. PubMed ID: 36868895
[TBL] [Abstract][Full Text] [Related]
45. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
Burkhardt B; Mueller S; Khanam T; Perkins SL
Br J Haematol; 2016 May; 173(4):545-59. PubMed ID: 26991119
[TBL] [Abstract][Full Text] [Related]
46. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
47. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
48. Coincidence of de novo T-lymphoblastic lymphoma and cutaneous gamma/delta peripheral T-cell lymphoma.
Satoh T; Kayano H; Kohri M; Tanae K; Asou C; Takahashi N; Tsukasaki K; Yasuda M
J Clin Exp Hematop; 2023; 63(4):257-261. PubMed ID: 38148016
[TBL] [Abstract][Full Text] [Related]
49. Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea.
Chang MH; Kim SJ; Kim K; Oh SY; Lee DH; Huh J; Ko YH; Choi CW; Yang DH; Won JH; Kim WS; Suh C
Leuk Lymphoma; 2009 Jul; 50(7):1119-25. PubMed ID: 19557632
[TBL] [Abstract][Full Text] [Related]
50. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
Burkhardt B; Hermiston ML
Br J Haematol; 2019 Jun; 185(6):1158-1170. PubMed ID: 30809797
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
52. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
Bayón-Calderón F; Toribio ML; González-García S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
[TBL] [Abstract][Full Text] [Related]
53. A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.
Newman H; Teachey DT
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955734
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.
Gao J; Van Meter M; Hernandez Lopez S; Chen G; Huang Y; Ren S; Zhao Q; Rojas J; Gurer C; Thurston G; Kuhnert F
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31399482
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
56. B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
Fang H; Wang W; El Hussein S; Morita K; Beird HC; Mitra A; Loghavi S; Lin P; Jabbour EJ; Khoury JD
Br J Haematol; 2021 Sep; 194(6):1034-1038. PubMed ID: 34402058
[TBL] [Abstract][Full Text] [Related]
57. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
58. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
59. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
60. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
